Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Treasury Shares for 3 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $384.6 million, compared with a TTM value of $384.6 million through Dec 2025, changed N/A, and an annual FY2025 reading of $384.6 million, changed N/A over the prior year.
  • Treasury Shares was $384.6 million for Q4 2025 at Keros Therapeutics.
  • Across five years, Treasury Shares topped out at $21.1 million in Q4 2025 and bottomed at $721700.0 in Q3 2025.